Sequenom's Shares Soar on Launch of Fetal Sex Determination Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Shares of Sequenom were up 14 percent in mid-afternoon trade on the Nasdaq after the firm announced earlier today the launch of its SensiGene Fetal (XY) test through its CLIA lab, the Sequenom Center for Molecular Medicine.

The new SensiGene test is a non-invasive assay that detects circulating cell-free fetal DNA in maternal blood. It interrogates male specific targets on the Y chromosome and runs on Sequenom's MassArray system.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.